Vetr cut shares of Pfizer, Inc. (NYSE:PFE) from a buy rating to a hold rating in a research report sent to investors on Wednesday. Vetr currently has $35.71 price target on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the stock. Citigroup Inc. downgraded shares of Pfizer from a neutral rating to a sell rating and dropped their target price for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Credit Suisse Group downgraded shares of Pfizer from an outperform rating to a neutral rating and dropped their target price for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Zacks Investment Research raised shares of Pfizer from a sell rating to a hold rating in a research report on Friday, July 14th. Morgan Stanley reissued a neutral rating and set a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Finally, ValuEngine downgraded shares of Pfizer from a buy rating to a hold rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $37.72.

Shares of Pfizer (NYSE PFE) opened at 35.36 on Wednesday. The stock has a market cap of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00. Pfizer has a one year low of $29.83 and a one year high of $35.84. The company has a 50-day moving average of $33.64 and a 200 day moving average of $33.53.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 EPS. On average, analysts predict that Pfizer will post $2.56 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/17/pfizer-inc-pfe-downgraded-by-vetr-inc-to-hold.html.

The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock worth $15,813,961 over the last three months. 0.06% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Franklin Resources Inc. raised its position in Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after acquiring an additional 389,629 shares during the period. Dimensional Fund Advisors LP raised its position in Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after acquiring an additional 2,028,313 shares during the period. Fisher Asset Management LLC raised its position in Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after acquiring an additional 1,275,832 shares during the period. Finally, LSV Asset Management raised its position in Pfizer by 0.6% during the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after acquiring an additional 199,100 shares during the period. Institutional investors own 69.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.